Biotene

ApprovedSmall molecule

UUniversity of Southern California

Biotene is one of 49 small molecule programs targeting Xerostomia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

XerostomiaActive, not recruiting

Oral MucositisActive, not recruiting

XerostomiaApproved

Active, not recruiting

Oral MucositisPhase 3

Active, not recruiting

Competition

Competitive Landscape

132 competitors in Oral Mucositis

#DrugCompanyPhaseTrials

Afinitor

Novartis

Phase 3

1 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

2 4

Duragesic

CCephalon

Phase 3

2 5

Neurontin

VViatris Specialty LLC

Phase 3

1 6

Bactroban

PPadagis LLC

Phase 3

1 7

Benadryl

PParkedale

Phase 3

1 8

Curcumin

Merck & Co.

Phase 3

2 9

N-Acetyl Cyteien

SStanford University

Phase 3

2 10

Zinc Acetate

NNobelpharma

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Radiotherapy1 trial

Mouth Care Regimes During Radiotherapy

Completed·SSt George Hospital, Australia·Phase 4·NCT00138827·50 enrolled

Xerostomia1 trial

Use of Biotene Moisturizing Mouth Spray for Xerostomia Associated With Oral Oxybutynin Use

Withdrawn·UUniversity of Southern California·Phase 4·NCT02522936

Oral Mucositis1 trial

Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy

Terminated·MMedical College of Wisconsin·Phase 3·NCT02539342·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Biotene. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biotene compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biotene. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Southern California company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Southern California

Biotene

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Radiotherapy1 trial

Xerostomia1 trial

Oral Mucositis1 trial

References

Drug Info

Quick Facts

Related News